Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Sponsor
Swiss Cancer Institute
Study ID
NCT03213301
Phase
PHASE2
Status
Completed

Conditions

  • Malignant Pleural Mesothelioma, Advanced

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.

Key Dates

Start date
Sep 28, 2017
Status verified
Jul 2021
Primary completion
Jun 11, 2021
Completion
Jun 11, 2021

Study Design

Enrollment
42 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lurbinectedin
    Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.

Primary Outcome Measure

Progression free survival (PFS) at 12 weeks [ Time Frame: at 12 weeks ]

Related Studies